Marieke Coenen associate professorMy research group performs pharmacogenetic research, from gene-finding to clinical implementation, with the aim to optimise treatment for the individual patient. I started my group on pharmacogenetics focussing on gene-finding in rheumatoid arthritis, for which I set up a productive international collaboration. I led the first genome-wide association analysis for anti-TNF treatment outcome (PMID:23233654) and the first large-scale genetic study showing how proxy measures for standard clinical outcomes can successfully be applied (PMID: 25114059). I have since extended my pharmacogenetic studies to other disorders, including psoriasis, inflammatory bowel disease (IBD), and childhood osteosarcoma.
In addition to my work on gene-finding, I aim to push the uptake of pharmacogenetics into clinical care. For this, I led the world-wide largest randomized controlled trial for cost-effectiveness of thiopurine-S-methyltransferase genotyping prior to thiopurine treatment in IBD (PMID:26072396). I currently co-supervise a similar multicentre study in psychiatry investigating the cost-effectiveness of pharmacogenetic testing prior to tricyclic anti-depressants treatment.
I am also responsible for the diagnostic pharmacogenetic testing at the Radboudumc.
Personal prizes & awards national & international
- 2006: VENI grant on pharmacogenetics of anti-TNF treatment
- Board member of the “Netwerk Klinische Farmacogenetica Nederland”.
- Board member of the Netherland Network of Precision Medicine (NNPM). This network is a platform for people working in the field of precision medicine (in The Netherlands) to meet and exchange ideas.
- Board member Genetics of Osteosarcoma consortium